Dr Falk Logo Blue

Mode of Action

  • Naronapride is a novel pro-kinetic agent with a unique combination of both 5HT4 agonistic and D2 antagonistic properties.
  • It is locally active in the gut lumen and designed to be minimally absorbable
  • Side-effect profile is similar to placebo with no cardiovascular liabilities observed in comprehensive TQT study


NAT-19/GPX (MOVE-IT): Dose-Finding Phase 2 Trial

Study Design

Falk Naronapride StudyDesign

Trial Population

  • Women or men between ≥18 and ≤75 years of age
  • Idiopathic or diabetic gastroparesis for more than 3 months
  • Evidence of delayed gastric emptying
  • Absence of mechanical obstructions

Trial Countries

Falk StudyCountries Falk (2)


  • France
  • Belgium
  • The Netherlands
  • Poland
  • Germany
  • Switzerland
  • Austria
  • UK

Contact us now

    Send us your request and receive further study details and the feasibility questionnaire to check if you can join this study.

    Please do not include any medical information in this field.

    * indicates a required field

    This form collects your personal data (name, email address, contact telephone and address - plus any additional information you wish to share with us) for the purpose of allowing us to contact you in regards to the clinical study/studies you are expressing interest in on submission of this form. By submitting this form, you also agree to your personal information being sent via email to the Future for Patients team in order for them to contact you. You can read our Privacy Policy for more information on how we protect and manage your submitted data.

    Yes, I consent to Future for Patients collecting my name, email address, contact telephone and address plus any additional information I have provided in this form submission. I also confirm that I understand that I should not disclose any medical information in this form.

    I would also like to be added to your mailing list to receive email newsletters from Future for Patients.